



## Immune Responses to Influenza Virus Antigens

Guest Editor:

### Dr. Lynda Coughlan

Department of Microbiology,  
Icahn School of Medicine at  
Mount Sinai, New York, NY 10029,  
USA

Deadline for manuscript  
submissions:

**closed (15 April 2021)**

### Message from the Guest Editor

The successful development of a universal influenza virus vaccine, which provides broad and durable protection, is a long-standing goal in the field.

The sub-optimal performance of traditional influenza vaccines has paved the way for the development of next-generation universal influenza virus vaccines using structurally stabilized or chimeric antigens, in the form of recombinant protein, viral vectors or nanoparticle-based platforms.

In this special issue, we encourage the submission of articles which present advances in our understanding of human immune responses to natural infection or immunization, studies which evaluate the immunogenicity and efficacy of novel universal influenza vaccines in animals or in clinical trials, as well as efforts to increase our understanding of the longevity of immunity directed towards cross-reactive epitopes.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)